Can the new medical insurance catalog still produce 1 billion yuan "magic medicine"?

Source: Medical Economic News March 8, 2017 the Ministry of human resources and social security released the 2017 medical insurance drug catalog on February 23 For the new catalog, there are different interpretations in the industry One interpretation is that "who is predicted to be the next product with annual sales of up to RMB 1 billion due to the market explosion due to being entered into the new medical insurance catalog" According to the revision of the medical insurance catalog in 2009, some products have been rocketed up and become the "magic drug" with annual sales of up to RMB 1 billion " The author holds different views on this prediction Because the medical market environment in 2009 is totally different from today's, the medical reform started in the second half of 2015 has completely subverted the previous policy and market pattern, and it is not appropriate to continue to use the traditional inertial thinking, so the conclusion is definitely wrong Medical network, March 8, February 23, the Ministry of human resources and social security released the 2017 version of the medical insurance drug catalog For the new catalog, there are different interpretations in the industry One interpretation is that "who is predicted to be the next product with annual sales of up to RMB 1 billion due to the market explosion due to being entered into the new medical insurance catalog" According to the revision of the medical insurance catalog in 2009, some products have been rocketed up and become the "magic drug" with annual sales of up to RMB 1 billion " The author holds different views on this prediction Because the medical market environment in 2009 is totally different from today's, the medical reform started in the second half of 2015 has completely subverted the previous policy and market pattern, and it is not appropriate to continue to use the traditional inertial thinking, so the conclusion is definitely wrong The market environment has changed to judge the impact of the new medical insurance catalog on the pharmaceutical market or the performance of pharmaceutical enterprises We cannot simply look at the catalog itself The new catalogue is only an important part of the new medical reform The trend of the medical market is the result of the comprehensive function of the whole medical reform The product marketing of the medical enterprises is a miniature of the trend of the whole medical market There is no doubt about the importance of products entering the medical insurance catalogue Especially for chronic disease products, because patients need long-term medication, the impact of entering the medical insurance on the use and sales of products should not be underestimated, but in today's context, it is almost impossible to produce a few billion yuan of "God medicine" And it's not hard to find that not every product entered into the health insurance catalog (such as the 2009 health insurance catalog) can lead to explosive sales growth Almost every "magic medicine" has one common characteristic - injection dosage form, especially antibiotic and traditional Chinese medicine injection These "magic drugs" can quickly increase to the annual sales of RMB 1 billion, relying on improper sales methods and transitional use Some kinds of "magic medicine" can be used in every department and cannot be used independently Most of these "omnipotent magic drugs" are sold by the bottom price agency mode With high commissions and kickbacks, the annual sales of several billion yuan can be realized quickly without academic promotion At present, the "two vote system" has been a national level policy, and there is no doubt that it has been firmly implemented In addition, ticket verification, tax verification and so on have made the traditional bottom price agency mode no longer popular The anti drug kickback, doctor's salary reform and multi-point practice have also increased the risk of sales with money, which can only lead to the end of life In addition to the payment policy and use supervision of medical insurance drugs, there is no "artifact" to make "Shenyao", and it is difficult to believe that "Shenyao" can reappear in the Jianghu Reevaluation of traditional Chinese medicine injection 2017 medical insurance drug catalog fully respects the opinions of medical experts, from which we can see the attitude of medical experts in different treatment fields For example: Traditional Chinese medicine injection, a controversial drug, has a high level of data in the statistics of adverse reactions of CFDA It can not be used as an independent treatment drug, but also takes up a large medical cost It has been called a category of "omnipotent magic medicine" by the industry The proportion of traditional Chinese medicine injection in the field of tumor treatment in the new version of medical insurance catalog is relatively large, and there is no restriction on the use of Chinese medicine injection in hospitals above grade II It is of little significance to restrict the use of Chinese medicine injection in the middle and late stage or radiotherapy and chemotherapy Because the early use of traditional Chinese medicine injection in cancer is not much, and most cancer patients need chemotherapy and radiotherapy, so this limitation is only literal The traditional Chinese medicine injection containing ginseng in the formula is listed in the catalogue of auxiliary drugs in the new catalogue, and the payment standard will be limited However, most of the traditional Chinese medicine injections in other treatment fields are limited to use in hospitals above the second level, or to specific indications Therefore, whether traditional Chinese medicine injection is necessary for cancer patients or whether experts in the field of cancer are infected by the medical market remains to be discussed However, it cannot be avoided that medical experts in various fields are an important part of the previous pattern of medical interests It is worth noting that on February 27, the re evaluation of the safety and effectiveness of traditional Chinese medicine injection was put on the important work schedule by the State Drug Administration, which is also an important measure to strengthen the management of drug quality after the consistency evaluation of chemical drugs It can be predicted that those traditional Chinese medicine injections with simple and rough manufacturing process, poor quality control and low safety will be eliminated in the process of re evaluation, which will play a role in inhibiting the barbaric growth of traditional Chinese medicine injections Greatly meet the needs of treatment On February 20, just two days before the new version of the medical insurance catalog was officially released, the Ministry of finance, the Ministry of human resources and social security and the state health and Family Planning Commission issued the opinions on strengthening the budget management of basic medical insurance funds and playing a role in controlling medical insurance funds At the beginning, it was pointed out that the unreasonable increase of medical expenses partially offset the effect of government investment and increased the burden on society and individuals 。 Therefore, controlling the unreasonable increase of medical expenses is the top priority of the document The document clearly stated that it would establish and improve the incentive and restraint mechanism of "surplus retention, reasonable over expenditure sharing", and encourage medical institutions to improve service efficiency and quality In areas where payment methods are implemented, such as payment by disease, payment by head and payment by bed day, if the actual expenses incurred by the medical institution are lower than the agreed payment standard, the surplus part shall be retained by the medical institution; if the actual expenses exceed the agreed payment standard, the excess part shall be borne by the medical institution, and for the reasonable excess part, the medical institution and the medical insurance base may, on the basis of negotiation and negotiation Gold sharing This will mean that in the future, doctors will have to be careful in their medication and consumables China's medical industry will enter the era of strong medical insurance supervision, and will be more and more strict! We believe that with the strict anti drug restriction order, the re evaluation of the safety and effectiveness of traditional Chinese medicine injection, the restriction of outpatient infusion, the control of medical insurance fund, and the parallel of a series of important measures of medical reform mentioned above, all policies are linked and cooperated with each other, and the soil for rapidly producing 1 billion yuan level "Shenyao" no longer exists The original intention of expanding the scope of the medical insurance catalogue is to guarantee the medical treatment needs of the people to a greater extent, and it is impossible to produce "magic medicine" To judge the impact of the new medical insurance catalog on the pharmaceutical market or the performance of pharmaceutical enterprises, we cannot simply look at the catalog itself The new catalogue is only an important part of the new medical reform The trend of the medical market is the result of the comprehensive function of the whole medical reform The product marketing of the medical enterprises is a miniature of the trend of the whole medical market There is no doubt about the importance of products entering the medical insurance catalogue Especially for chronic disease products, because patients need long-term medication, the impact of entering the medical insurance on the use and sales of products should not be underestimated, but in today's context, it is almost impossible to produce a few billion yuan of "God medicine" And it's not hard to find that not every product entered into the health insurance catalog (such as the 2009 health insurance catalog) can lead to explosive sales growth Almost every "magic medicine" has one common characteristic - injection dosage form, especially antibiotic and traditional Chinese medicine injection These "magic drugs" can quickly increase to the annual sales of RMB 1 billion, relying on improper sales methods and transitional use Some kinds of "magic medicine" can be used in every department and cannot be used independently Most of these "omnipotent magic drugs" are sold by the bottom price agency mode With high commissions and kickbacks, the annual sales of several billion yuan can be realized quickly without academic promotion At present, the "two vote system" has been a national level policy, and there is no doubt that it has been firmly implemented In addition, ticket verification, tax verification and so on have made the traditional bottom price agency mode no longer popular The anti drug kickback, doctor's salary reform and multi-point practice have also increased the risk of sales with money, which can only lead to the end of life In addition to the payment policy and use supervision of medical insurance drugs, there is no "artifact" to make "Shenyao", and it is difficult to believe that "Shenyao" can reappear in the Jianghu Reevaluation of traditional Chinese medicine injection 2017 medical insurance drug catalog fully respects the opinions of medical experts, from which we can see the attitude of medical experts in different treatment fields For example: Traditional Chinese medicine injection, a controversial drug, has a high level of data in the statistics of adverse reactions of CFDA It can not be used as an independent treatment drug, but also takes up a large medical cost It has been called a category of "omnipotent magic medicine" by the industry The proportion of traditional Chinese medicine injection in the field of tumor treatment in the new version of medical insurance catalog is relatively large, and there is no restriction on the use of Chinese medicine injection in hospitals above grade II It is of little significance to restrict the use of Chinese medicine injection in the middle and late stage or radiotherapy and chemotherapy Because the early use of traditional Chinese medicine injection in cancer is not much, and most cancer patients need chemotherapy and radiotherapy, so this limitation is only literal The traditional Chinese medicine injection containing ginseng in the formula is listed in the catalogue of auxiliary drugs in the new catalogue, and the payment standard will be limited However, most of the traditional Chinese medicine injections in other treatment fields are limited to use in hospitals above the second level, or to specific indications Therefore, whether traditional Chinese medicine injection is necessary for cancer patients or whether experts in the field of cancer are infected by the medical market remains to be discussed However, it cannot be avoided that medical experts in various fields are an important part of the previous pattern of medical interests It is worth noting that on February 27, the re evaluation of the safety and effectiveness of traditional Chinese medicine injection was put on the important work schedule by the State Drug Administration, which is also an important measure to strengthen the management of drug quality after the consistency evaluation of chemical drugs It can be predicted that those traditional Chinese medicine injections with simple and rough manufacturing process, poor quality control and low safety will be eliminated in the process of re evaluation, which will play a role in inhibiting the barbaric growth of traditional Chinese medicine injections Greatly meet the needs of treatment On February 20, just two days before the new version of the medical insurance catalog was officially released, the Ministry of finance, the Ministry of human resources and social security and the state health and Family Planning Commission issued the opinions on strengthening the budget management of basic medical insurance funds and playing a role in controlling medical insurance funds At the beginning, it was pointed out that the unreasonable increase of medical expenses partially offset the effect of government investment and increased the burden on society and individuals 。 Therefore, controlling the unreasonable increase of medical expenses is the top priority of the document The document clearly stated that it would establish and improve the incentive and restraint mechanism of "surplus retention, reasonable over expenditure sharing", and encourage medical institutions to improve service efficiency and quality real